F021 New Drugs, New Rashes: An Update on Cutaneous Drug Eruptions
DESCRIPTION
Adverse drug reactions are inevitable sequelae of contemporary medical management and mucocutaneous eruptions rank among the most common of these reactions. Newer medications with significant drug eruption rates, and serious or characteristic cutaneous effects include newer anticancer drugs and the biologics. Distinctive reaction patterns, such as toxic epidermal necrolysis-like eruptions, are also emerging. It is a challenge for the practicing dermatologist to stay abreast of these new drugs and new rashes. Additionally, knowledge and management of severe drug eruptions in constantly evolving. This session will provide a comprehensive update on these eruptions and their management.
LEARNING OBJECTIVES
Describe drug culprits and current management of severe cutaneous adverse reactions.
Recognize and manage drug-induced toxic epidermal necrosis-like eruptions.
Assess, evaluate and treat cutaneous toxicities of new anticancer drugs and biologic therapies.
SCHEDULE
1:00 PM
SCAR update: DRESS/TEN
Helena Beth Pasieka, MD
1:20 PM
Drug-induced TEN-like conditions
Susan Burgin, MD, FAAD
1:40 PM
Cutaneous side effects of biologic therapies
Jeffrey Marcus Cohen, MD, FAAD
2:00 PM
Q and A
Susan Burgin, MD, FAAD, Jeffrey Marcus Cohen, MD, FAAD, Helena Beth Pasieka, MD
2:10 PM
Cutaneous side effects of immune checkpoint inhibitors (ICIs)
Jennifer N. Choi, MD, FAAD
2:30 PM
Cutaneous side effects of oncology drugs other than ICIs
Connie Shi, MD, FAAD
2:50 PM
Q and A
Jennifer N. Choi, MD, FAAD, Connie Shi, MD, FAAD
DIRECTOR
Susan Burgin, MD, FAAD
SPEAKERS
Jennifer N. Choi, MD, FAAD
Jeffrey Marcus Cohen, MD, FAAD
Helena Beth Pasieka, MD
Connie Shi, MD, FAAD
HANDOUTS
DISCLOSURES
Susan Burgin, MD, FAAD
VisualDx – Consultant(Honoraria);
Jennifer N. Choi, MD, FAAD
CeraVe/Valeante – Independent Contractor(Fees); Janssen Global Services, LLC – Advisory Board(Fees); La Roche-Posay Laboratorie Pharmaceutique – Advisory Board(Fees); OnQuality Pharmaceuticals, Ltd. – Advisory Board(Fees); PraHealth Sciences – Advisory Board(Fees); Pyxis Oncology – Advisory Board(Fees); Regeneron Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees);
Jeffrey Marcus Cohen, MD, FAAD
Advarra – Data Safety Monitoring Board(Fees); GlaxoSmithKline Immunology – Consultant (1099 relationship)(Honoraria); Logical Images, Inc – Consultant(Honoraria); Novartis – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria);
Helena Beth Pasieka, MD
No financial relationships exist with ineligible companies.
Connie Shi, MD, FAAD
No financial relationships exist with ineligible companies.